Michael A. Shirley

1.5k total citations
22 papers, 1.1k citations indexed

About

Michael A. Shirley is a scholar working on Molecular Biology, Pharmacology and Genetics. According to data from OpenAlex, Michael A. Shirley has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 6 papers in Pharmacology and 5 papers in Genetics. Recurrent topics in Michael A. Shirley's work include Retinoids in leukemia and cellular processes (9 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Estrogen and related hormone effects (5 papers). Michael A. Shirley is often cited by papers focused on Retinoids in leukemia and cellular processes (9 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Estrogen and related hormone effects (5 papers). Michael A. Shirley collaborates with scholars based in United States, Switzerland and United Kingdom. Michael A. Shirley's co-authors include Peter Schäfer, George W. Muller, William W. Lamph, Robert C. Murphy, R A Heyman, Eric D. Bischoff, Marco M. Gottardis, E H Ulm, David Stirling and J. Blake Bartlett and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Michael A. Shirley

22 papers receiving 1.1k citations

Peers

Countries citing papers authored by Michael A. Shirley

Since Specialization

Citations

This map shows the geographic impact of Michael A. Shirley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Shirley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Shirley more than expected).

Fields of papers citing papers by Michael A. Shirley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Shirley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Shirley. The network helps show where Michael A. Shirley may publish in the future.

Co-authorship network of co-authors of Michael A. Shirley

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Shirley. A scholar is included among the top collaborators of Michael A. Shirley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Shirley. Michael A. Shirley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity 2012 ·Bioorganic & Medicinal Chemistry Letters ·Alexander L. Ruchelman, Hon‐Wah Man, Weihong Zhang, Roger Chen, Lori Capone, Jian Kang, Anastasia Parton, Laura G. Corral, Peter Schäfer, Darius Babusis, Mehran F. Moghaddam, Yang Tang, Michael A. Shirley, George W. Muller	50
2	Metabolite Interference in Pharmacokinetic Studies 2007 ·Drug Metabolism Letters ·Mehran F. Moghaddam, (unknown), Yang Tang, Oleg G. Khatsenko, Jason D. Katz, Michael A. Shirley	1
3	The Synthetic Compound CC-5079 Is a Potent Inhibitor of Tubulin Polymerization and Tumor Necrosis Factor-α Production with Antitumor Activity 2006 ·Cancer Research ·Linghua Zhang, Lei Wu, Heather K. Raymon, Roger S. Chen, Laura G. Corral, Michael A. Shirley, Rama Krishna Narla, (unknown), George W. Muller, David Stirling, J. Blake Bartlett, Peter Schäfer, Faribourz Payvandi	77
4	Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro 2005 ·Microvascular Research ·Keith Dredge, (unknown), Simon P. Robinson, Linghua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George W. Muller, Peter Schäfer, David Stirling, Angus Dalgleish, J. Blake Bartlett	225
5	Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. 2001 ·PubMed ·Stanley R. Howell, Michael A. Shirley, Timothy A. Grese, David A. Neel, (unknown), E H Ulm	27
6	9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. 2000 ·PubMed ·Kongming Wu, Heetae Kim, (unknown), (unknown), S K Mohsin, Susan G. Hilsenbeck, William W. Lamph, Marco M. Gottardis, Michael A. Shirley, John G. Kuhn, (unknown), Powel H. Brown	54
7	A HPLC method for the determination of 9-cis retinoic acid (ALRT1057) and its 4-Oxo metabolite in human plasma 1998 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), Alfred Carlson, Gordon Loewen, Michael A. Shirley, (unknown)	6
8	Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes. 1998 ·PubMed ·Stanley R. Howell, Michael A. Shirley, E H Ulm	39
9	Oxidative metabolism of a rexinoid and rapid phase II metabolite identification by mass spectrometry. 1997 ·PubMed ·Michael A. Shirley, Pat Wheelan, Stanley R. Howell, Robert C. Murphy	12
10	Oxidative and reductive metabolism of 9-cis-retinoic acid in the rat. Identification of 13,14-dihydro-9-cis-retinoic acid and its taurine conjugate. 1996 ·Drug Metabolism and Disposition ·Michael A. Shirley, Youssef L. Bennani, Marcus F. Boehm, Alan P. Breau, Charles Pathirana, E H Ulm	27
11	Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. 1996 ·PubMed ·Marco M. Gottardis, Eric D. Bischoff, Michael A. Shirley, (unknown), William W. Lamph, R A Heyman	178
12	9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia 1995 ·Blood ·(unknown), (unknown), (unknown), (unknown), (unknown), Fabio Benedetti, (unknown), (unknown), E H Ulm, Michael A. Shirley	79
13	Taurine conjugation of ibuprofen in humans and in rat liver in vitro. Relationship to metabolic chiral inversion. 1994 ·Journal of Pharmacology and Experimental Therapeutics ·Michael A. Shirley, Xiangming Guan, David G. Kaiser, Gordon W. Halstead, Thomas A. Baillie	37
14	Stereochemical studies on the beta-oxidation of valproic acid in isolated rat hepatocytes. 1993 ·Drug Metabolism and Disposition ·Michael A. Shirley, Pei Hu, Thomas A. Baillie	8
15	Chemotactic LTB4 metabolites produced by hepatocytes in the presence of ethanol 1992 ·Biochemical and Biophysical Research Communications ·Michael A. Shirley, (unknown), Robert C. Murphy	22
16	Metabolic activation of unsaturated derivatives of valproic acid: role of microsomal versus mitochondrial enzyme systems 1992 ·Journal of Basic and Clinical Physiology and Pharmacology ·Thomas A. Baillie, Kelem Kassahun, Mark P. Grillo, Pei Hu, Michael A. Shirley, Jing Lin, R H Lévy	14
17	Novel 3-hydroxylated leukotriene b₄metabolites from ethanol-treated rat hepatocytes 1992 ·Journal of the American Society for Mass Spectrometry ·Michael A. Shirley, Robert C. Murphy	4
18	Metabolism of LTB₄ by Isolated Hepatocytes: New Metabolites and Effect of Ethanol^a 1991 ·Annals of the New York Academy of Sciences ·Michael A. Shirley, Robert C. Murphy	3
19	(30] Leukotriene metabolism by isolated rat hepatocytes 1990 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Michael A. Shirley, (unknown)	1
20	Metabolism of leukotriene B4 in isolated rat hepatocytes. Involvement of 2,4-dienoyl-coenzyme A reductase in leukotriene B4 metabolism. 1990 ·Journal of Biological Chemistry ·Michael A. Shirley, Robert C. Murphy	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact